Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Binghe Xu
CONTACT
Lead
Eddingpharm (Zhuhai) Co., Ltd.
The Phase Ib part of the study will primarily assess the safety and tolerability of GB268 in combination therapies, including dose-limiting toxicities (DLTs). The Phase II part will primarily evaluate the preliminary anti-tumor activity of GB268 as monotherapy and in various combination regimens in corresponding breast cancer populations.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted